FDA Advisory Committee Unanimously Recommends Approval of Investigational Luxturna (voretigene neparvovec) for Patients with Biallelic RPE65-mediated Inherited Retinal Disease

PHILADELPHIA, Oct. 12, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that the U.S. Food and Drug Administration ’s...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news